# Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

> **NCT03452501** · — · COMPLETED · sponsor: **Hikma Pharmaceuticals LLC** · enrollment: 157 (actual)

## Conditions studied

- Inflammatory Bowel Diseases
- Crohn Disease
- Fistulizing Crohn's Disease
- Ulcerative Colitis

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT03452501
- **Lead sponsor:** Hikma Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-26
- **Primary completion:** 2020-08-17
- **Final completion:** 2020-08-17
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2021-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452501, "Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03452501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*